Semaglutide Use in Elderly Obese Patients

NCT05302596 on ClinicalTrials.gov · last registry update 2025-04-17

A small phase 2 — 16 participants, against a typical 110. The sponsor logged completion for 23 October 2023. Primary outcome, as filed: Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: State University of New York at Buffalo
Sponsor type: Other
Enrollment: 16
Started: 2022-09-01
Primary completion: 2023-10-23 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio

Conditions studied

Obesity · Aging

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.